WO2008032928A1 - Method for preparing bone grafting substitute from horse bone - Google Patents
Method for preparing bone grafting substitute from horse bone Download PDFInfo
- Publication number
- WO2008032928A1 WO2008032928A1 PCT/KR2007/003686 KR2007003686W WO2008032928A1 WO 2008032928 A1 WO2008032928 A1 WO 2008032928A1 KR 2007003686 W KR2007003686 W KR 2007003686W WO 2008032928 A1 WO2008032928 A1 WO 2008032928A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bone
- powder
- graft substitute
- horse
- preparing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/46—Special tools or methods for implanting or extracting artificial joints, accessories, bone grafts or substitutes, or particular adaptations therefor
- A61F2/4644—Preparation of bone graft, bone plugs or bone dowels, e.g. grinding or milling bone material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3608—Bone, e.g. demineralised bone matrix [DBM], bone powder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3641—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
- A61L27/3645—Connective tissue
- A61L27/365—Bones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
- A61F2002/2817—Bone stimulation by chemical reactions or by osteogenic or biological products for enhancing ossification, e.g. by bone morphogenetic or morphogenic proteins [BMP] or by transforming growth factors [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
- A61F2002/2835—Bone graft implants for filling a bony defect or an endoprosthesis cavity, e.g. by synthetic material or biological material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/46—Special tools or methods for implanting or extracting artificial joints, accessories, bone grafts or substitutes, or particular adaptations therefor
- A61F2/4644—Preparation of bone graft, bone plugs or bone dowels, e.g. grinding or milling bone material
- A61F2002/4649—Bone graft or bone dowel harvest sites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/112—Phosphorus-containing compounds, e.g. phosphates, phosphonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
- A61L2300/406—Antibiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Definitions
- the present invention relates to the method for preparing the bone graft substitute using horse bone, and more particularly to the method for preparing the bone r.graft substitute, which does not cause a xenogenic immune response and has no risk of infection with Creutzfeldt Jakob Disease, which has a potential to occur when bovine bone is used in xenogenic bone grafting.
- the method comprising treating horse bone with sodium hypochlorite, treating hydrothermally the treated bone at the temperature higher than 121 ° C under a pressure, and then heat- treating the hydrothermally treated bone at the temperature higher than 500 ° C .
- bone graft substitute refers to a graft material, which can be used to fill spaces in bone tissues and to promote the formation of new bone, when bone defects are created by various dental diseases, trauma, degeneration caused by disease, or other loss of tissue.
- the best graft material is known to be autogenous bone which is taken from the patient's own bone.
- the autogenous bone graft has problems in that it requires secondary surgery, is difficult to obtain the required amount, can be absorbed into the body early, is difficult to perform in small-size hospitals and can make the patient's pain and disease conditions severe.
- bone graft substitutes including donated human bone, artificial bone, and synthetic materials comprising bone component (hydroxyapatite), have been used in bone grafting.
- Commercial bone graft substitutes are available in several forms, including powders, gels, slurry/putties, tablets, chips, morsels, pellets, sticks, sheets and blocks.
- Such bone graft substitutes have the following advantages: ensuring product consistency; less risk for infection and disease; no morbidity or pain caused by harvesting of the patient's own bone for grafting; and availability of the substitute in different volumes (that is, it is not limited by the harvest site in patients).
- they are greatly different from human bone, and thus have various problems, including slow tissue regeneration rate.
- bone graft substitutes have been prepared by physically and chemically treating animal bone, having a structure similar to that of human bone, to remove organic materials and recover only inorganic components from the animal bone, and processing the inorganic components into graft materials, which can be used in dental or orthopedic surgery.
- Typical commercial products, prepared using this method may include Bio-Oss ® (Geistlich Biomaterials).
- the method for preparing bone graft materials using animal bone comprises the steps of: degreasing bovine femur by refluxing it in a solvent having a boiling point of 80-120 ° C ; heating the degreased bovine bone with ammonia or primary amine to remove proteins and organic matter, thus producing bone mineral; heating the bone mineral at a high temperature of 250-600 °C for a few hours; and drying the heated material (US Patent Nos. 5,167,961 and 5,417,975).
- prion that causes mad cow disease should be removed. Because the prion is not completely removed, even at a high temperature of 600 "C , it cannot be removed by the methods for preparing bone graft substitute, known to date. Thus, there is a need to develop a method of preparing bone graft substitutes using animal bone safe from mad cow disease.
- a bone graft substitute safe from mad cow disease can be prepared using the method comprising the steps of treating horse bone with sodium hypochlorite, which can degrade and inactivate prion and other proteins, treating hydrothermally the treated bone in purified water at the temperature higher than 121 ° C under a pressure to inactivate proteins, and then heat-treated the hydrothermally treated bone at 600 ° C , thereby completing the present invention.
- Another object of the present invention is to provide the bone graft substitute composition containing the bone graft substitute prepared according to said method.
- the method for preparing the bone graft substitute using horse bone comprising the steps of: (a) boiling horse bone, from which blood components have been removed, in purified water, to remove fatty substances and proteins from the bone, and then drying the boiled bone; (b) powdering the dried bone, and then soaking and shaking the bone powder in an organic solvent; (c) removing the organic solvent and then drying the remaining bone powder; (d) treating the dried bone powder with the 2-20% (w/v) solution of sodium hypochlorite; (e) removing the sodium hypochlorite solution and impurities from the bone powder, and then drying the remaining bone powder; (f) adding purified water to the bone powder, treating hydrothermally the bone powder solution at 120-125 °C for the time range from 30 minutes to 5 hours under a pressure, and then drying the hydrothermally
- the bone graft substitute composition containing, as an active ingredient, horse bone powder, which is prepared according to said method and has no risk of infection with mad cow disease and from which fatty substances, lipids and proteins have been removed so as not to cause a xenogenic immune response.
- FIG. 1 shows the results of XRD measurement of bone powder thermally treated at 600 ° C .
- the present invention relates to the method for preparing a bone graft substitute using horse bone, the method comprising the steps of: (a) boiling horse bone, from which blood components have been removed, in purified water, to remove fatty substances and proteins from the bone, and drying the boiled bone; (b) crushing the dried bone, and then soaking and shaking the bone powder in an organic solvent; (c) removing the organic solvent and then drying the remaining bone powder; (d) treating the dried bone powder with a 2-20% (w/v) solution of sodium hypochlorite; (e) removing the sodium hypochlorite solution and impurities from the bone powder, and then drying the remaining bone powder; (f) adding purified water to the bone powder, treating hydrothermally the bone powder solution at 120-125 °C for 30 minutes to 5 hours under a pressure, and then drying the hydrothermally treated powder; and (g) heat-treating the dried bone powder at 500-1000 ° C for 1-24 hours to completely remove lipids and proteins from the bone powder.
- the term "bone graft substitute” refers to a material for filling spaces in bone tissues.
- the bone graft substitute can be shaped in the form of, for example, putties, pastes, strips, blocks or chips, using a method such as pressing, compression, contact under pressure, packing, solidification or hardening.
- it can be formulated in the form of, for example, gels, granules, pastes, tablets or pellets, using chemical additives.
- it may also be used in the form of powder itself.
- the bone graft substitute When the bone graft substitute is formulated as described above to use, it is preferably used in combination with a biologically active substance.
- the biologically active substance include bone growth-promoting factors, fibrin, bone morphogenetic factors, bone growth-promoting agents, chemotherapeutic agents, antibiotic agents, analgesics, bisphosphonates, strontium salts, fluorine salts, magnesiukm salts, and sodium salts.
- the step (b) of soaking the bone powder in the organic solvent is carried out to remove fatty substances remaining in the horse bone powder.
- the organic solvent is preferably the mixed solvent of chloroform and methanol.
- the ratio of chloroform: methanol in the mixed solvent may be 2-8: 8-2, and preferably 1 :1.
- the step (d) of treating the bone powder with sodium hypochlorite solution is carried out to degrade and remove proteins remaining in the horse bone powder in a water-soluble state and to inactivate denatured prion proteins that cause mad cow disease.
- sodium hypochlorite may be used in the 2-20% (w/v) solution of sodium hypochlorite, and preferably the 4% (w/v) solution of sodium hypochlorite.
- the heat-treatment temperature in the step (g) is preferably 550-650 °C .
- steps (d) and (e) are carried out to remove proteins and organic substances.
- the bone powder is hydrothermally treated at 120-125 ° C for more than 30 minutes under a pressure, and preferably 3 hours, to degrade and remove proteins from the bone powder.
- the preparation method according to the present invention may additionally comprise, after the step (g), the step of sieving the heat-treated bone powder through the sieves having mesh size range of 212-425 ⁇ m, 425-1000 ⁇ m, 1000-2000 ⁇ m and 1000-3000 ⁇ m, respectively.
- the present invention relates to the bone graft substitute composition containing, as an active ingredient, horse bone powder, which is prepared according to the said method and has no risk of infection with mad cow disease and from which fatty substances, lipids and proteins have been removed so as not to cause a xenogenic immune response.
- the bone graft substitute composition according to the present invention preferably additionally contains one or more biologically active substances selected from the group consisting of bone growth-promoting factors, fibrin, bone morphogenetic factors, bone growth agents, chemotherapeutic agents, antibiotic agents, analgesics, bisphosphonates, strontium salts, fluorine salts, magnesiukm salts, and sodium salts.
- the bone graft substitute composition according to the present invention preferably additionally contains one or more chemical compounds selected from the group consisting of hyaluronic acid, chondroitin sulfate, alginate, chitosan, collagen, hydroxyapatite, calcium carbonate, calcium phosphate, calcium sulfate and ceramics.
- the growth factors include BMP (bone morphogenic protein), PDGF (platelet-derived growth factor), TGF-beta (transgenic growth factor), IGF-I (insulin-like growth factor), IGF-II, FGF (fibroblast growth factor) and BGDF-II (beta-2-microglobulin).
- BMP bone morphogenic protein
- PDGF platelet-derived growth factor
- TGF-beta transgenic growth factor
- IGF-I insulin-like growth factor
- IGF-II insulin-like growth factor
- FGF fibroblast growth factor
- BGDF-II beta-2-microglobulin
- the bone morphogenetic factors include osteocalcin, bonesialoprotein, osteogenin and BMP.
- the bone growth-promoting agent any substance may be used without limitation, as long as it is harmless to the human body and promote bone growth.
- the bone growth-promoting agents include peptides or nucleic acids, which promote bone formation, and antagonists against substances which inhibit bone formation.
- the chemical additives that are used to formulate the bone graft substitute include hyaluronic acid, collagen, hydroxyapatite, calcium carbonate, calcium phosphate, calcium sulfate and ceramics.
- the bone graft substitute can be formulated in the form of gels, strips, granules, chips, tablets or pastes.
- the bone graft substitute when the chemical compound is hyaluronic acid, can be formulated into a gel-type bone graft substitute composition.
- the step of treating the bone powder with sodium hypochlorite is preferably carried out for more than 72 hours in order to remove prion and the remaining proteins.
- Example 1 Method for preparing bone graft substitute
- Bone taken from the equine femur was cut with a bone cutter into pieces having a size of about 5 cm 3 .
- the bone pieces were soaked in purified water for 24 hours to remove blood components from the bone.
- the bone pieces, washed with deionized water, were boiled in purified water for 72 hours while replacing purified water at the interval of 12 hours, thus primarily removing fatty substances and proteins from the bone.
- the bone pieces, from which fat and proteins have been primarily removed, were completely dried in an oven at 60 "C for 24 hours and crushed with a pulverizer to a size of less than 10 mm 3 . [Degreasing process]
- 1 g of the degreased dried bone powder was added to 20 ml of the 4% (w/v) solution of sodium hypochlorite and shaken at a revolution speed of 120 rpm for 72 hours to remove proteins from the bone powder and to inactivate a prion protein that causes mad cow disease.
- 1 g of the bone powder was added to 50 g of purified water and shaken at 120 rpm for 72 hours, thus removing the remaining sodium hypochlorite.
- the purified water was replaced with fresh purified water at a 2-hr interval for 12 hours after the start of shaking, and then replaced with fresh purified water at a 12-hr interval.
- 1 g of the water- washed bone powder was added to 50 g of purified water and hydrothermally treated at 121 ° C for 3 hours under a pressure. Finally, the bone powder was completely dried in an oven at 60 ° C .
- Thermal treatment process The degreased, deproteinized, dried bone powder was heat-treated at high temperature to remove the remaining lipids and proteins. An electric furnace used in the heat-treatment was heated at a rate of 2 ° C/min, and the bone powder was thermally treated at 600 °C for 3 hours, and then cooled in the furnace.
- the thermally treated bone powder was sieved through sieves having mesh sizes of 212-425 ⁇ m, 425-1000 ⁇ m, 1000-2000 ⁇ m and 1000-3000 ⁇ m, respectively, and the sieved bone powder was washed several times with purified water to remove fine dust remaining on the surface thereof.
- the water-washed powder was dried in an oven at 60 °C for 24 hours and then collected for use as a bone graft substitute.
- the prepared bone graft substitute was analyzed by XRD and, as a result, it could be seen that the bone graft substitute consisted of pure apatite crystals (see FIG.
- Example 2 Method for preparing bone graft substitute composition
- the present invention provides a method for preparing a bone graft substitute, which comprises treating horse bone with a sodium hypochlorite solution, followed by hydrothermal treatment and high-temperature treatment. Also, the present invention provides the bone graft substitute composition containing the bone graft substitute prepared according to said method. According to the present invention, a bone graft substitute, which, when transplanted into the human body, does not cause immune responses and has no risk of infection with organic pathogenic substances such as a denatured prion protein that causes mad cow disease, can be prepared in a simple manner by effectively removing fatty substances and organic substances from horse bone having a structure highly similar to that of human bone.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Transplantation (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Materials For Medical Uses (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to a method for preparing a bone graft substitute using horse bone. More specifically, relates to the method for preparing a bone graft substitute, which does not cause a xenogenic immune response and has no risk of infection with mad cow disease, which can occur when bovine bone is used in xenogenic bone grafting, the method comprising treating horse bone with sodium hypochlorite, hydrothermally treating the treated bone under pressure at a temperature higher than 121 °C, and thermally treating the hydrothermally treated bone at higher than 500 °C. According to the disclosed method, a bone graft substitute, which, when transplanted into the human body, does not cause immune responses and has no risk of infection with organic pathogenic substances such as a denatured prion protein that causes mad cow disease, can be prepared in a simple manner by effectively removing fatty substances and organic substances from horse bone having a structure highly similar to that of human bone.
Description
Method for Preparing Bone Grafting Substitute from Horse Bone
TECHNICAL FIELD
The present invention relates to the method for preparing the bone graft substitute using horse bone, and more particularly to the method for preparing the bone r.graft substitute, which does not cause a xenogenic immune response and has no risk of infection with Creutzfeldt Jakob Disease, which has a potential to occur when bovine bone is used in xenogenic bone grafting. The method comprising treating horse bone with sodium hypochlorite, treating hydrothermally the treated bone at the temperature higher than 121 °C under a pressure, and then heat- treating the hydrothermally treated bone at the temperature higher than 500 °C .
BACKGROUND ART
As used herein, the term "bone graft substitute" (BGS) refers to a graft material, which can be used to fill spaces in bone tissues and to promote the formation of new bone, when bone defects are created by various dental diseases, trauma, degeneration caused by disease, or other loss of tissue. Generally, the best graft material is known to be autogenous bone which is taken from the patient's own bone. However, the autogenous bone graft has problems in that it requires secondary surgery, is difficult to obtain the required amount, can be absorbed into the body early, is difficult to perform in small-size hospitals and can make the patient's pain and disease conditions severe.
For this reason, various bone graft substitutes, including donated human bone, artificial bone, and synthetic materials comprising bone component (hydroxyapatite), have been used in bone grafting. Commercial bone graft
substitutes are available in several forms, including powders, gels, slurry/putties, tablets, chips, morsels, pellets, sticks, sheets and blocks. Such bone graft substitutes have the following advantages: ensuring product consistency; less risk for infection and disease; no morbidity or pain caused by harvesting of the patient's own bone for grafting; and availability of the substitute in different volumes (that is, it is not limited by the harvest site in patients). However, they are greatly different from human bone, and thus have various problems, including slow tissue regeneration rate.
In an attempt to solve such problems, bone graft substitutes have been prepared by physically and chemically treating animal bone, having a structure similar to that of human bone, to remove organic materials and recover only inorganic components from the animal bone, and processing the inorganic components into graft materials, which can be used in dental or orthopedic surgery. Typical commercial products, prepared using this method, may include Bio-Oss® (Geistlich Biomaterials).
The method for preparing bone graft materials using animal bone comprises the steps of: degreasing bovine femur by refluxing it in a solvent having a boiling point of 80-120°C ; heating the degreased bovine bone with ammonia or primary amine to remove proteins and organic matter, thus producing bone mineral; heating the bone mineral at a high temperature of 250-600 °C for a few hours; and drying the heated material (US Patent Nos. 5,167,961 and 5,417,975).
An example of treating a cartilage with sodium hypochlorite to selectively remove the collagen phase in order to observe the remaining cartilage structure was reported (Broz, JJ. et ai, J. Mater. ScL Mater. Med., 8:395, 1997). However, an example of using sodium hypochlorite to remove all proteins in the preparation of bone mineral has not yet been reported.
Among such animal bones, bovine bone is most frequently used, and the product Bio-Oss® is also produced using bovine bone as a raw material. However, as the onset of mad cow disease (bovine spongiform encephalopathy or Creutzfeldt- Jacob disease) has recently become frequent, the safety of cattle as a raw material from mad cow disease cannot be secured. For this reason, in a step of processing bovine bone into bone graft substitutes, prion that causes mad cow disease should be removed. Because the prion is not completely removed, even at a high temperature of 600 "C , it cannot be removed by the methods for preparing bone graft substitute, known to date. Thus, there is a need to develop a method of preparing bone graft substitutes using animal bone safe from mad cow disease.
Accordingly, the present inventors have found that a bone graft substitute safe from mad cow disease can be prepared using the method comprising the steps of treating horse bone with sodium hypochlorite, which can degrade and inactivate prion and other proteins, treating hydrothermally the treated bone in purified water at the temperature higher than 121 °C under a pressure to inactivate proteins, and then heat-treated the hydrothermally treated bone at 600 °C , thereby completing the present invention.
SUMMARY OF THE INVENTION
It is an object of the present invention to provide the method for preparing the bone graft substitute using horse bone, the method comprising treating horse bone with a sodium hypochlorite solution and further treating the treated bone at high temperature.
Another object of the present invention is to provide the bone graft substitute composition containing the bone graft substitute prepared according to said method.
To achieve the above objects, according to one aspect of the present invention, there is provided the method for preparing the bone graft substitute using horse bone, the method comprising the steps of: (a) boiling horse bone, from which blood components have been removed, in purified water, to remove fatty substances and proteins from the bone, and then drying the boiled bone; (b) powdering the dried bone, and then soaking and shaking the bone powder in an organic solvent; (c) removing the organic solvent and then drying the remaining bone powder; (d) treating the dried bone powder with the 2-20% (w/v) solution of sodium hypochlorite; (e) removing the sodium hypochlorite solution and impurities from the bone powder, and then drying the remaining bone powder; (f) adding purified water to the bone powder, treating hydrothermally the bone powder solution at 120-125 °C for the time range from 30 minutes to 5 hours under a pressure, and then drying the hydrothermally treated powder; and (g) heat-treating the dried bone powder at 500-1000 °C for 1-24 hours to completely remove lipids and proteins from the bone powder.
According to another aspect of the present invention, there is provided the bone graft substitute composition containing, as an active ingredient, horse bone powder, which is prepared according to said method and has no risk of infection with mad cow disease and from which fatty substances, lipids and proteins have been removed so as not to cause a xenogenic immune response.
Other features and aspects of the present invention will be apparent from the following detailed description and the appended claims.
BRIEF DESCRIPTION OF DRAWINGS
FIG. 1 shows the results of XRD measurement of bone powder thermally treated at 600°C .
DETAILED DESCRIPTION OF THE INVENTION, AND PPRFERRED EMBODIMENTS
In one aspect, the present invention relates to the method for preparing a bone graft substitute using horse bone, the method comprising the steps of: (a) boiling horse bone, from which blood components have been removed, in purified water, to remove fatty substances and proteins from the bone, and drying the boiled bone; (b) crushing the dried bone, and then soaking and shaking the bone powder in an organic solvent; (c) removing the organic solvent and then drying the remaining bone powder; (d) treating the dried bone powder with a 2-20% (w/v) solution of sodium hypochlorite; (e) removing the sodium hypochlorite solution and impurities from the bone powder, and then drying the remaining bone powder; (f) adding purified water to the bone powder, treating hydrothermally the bone powder solution at 120-125 °C for 30 minutes to 5 hours under a pressure, and then drying the hydrothermally treated powder; and (g) heat-treating the dried bone powder at 500-1000 °C for 1-24 hours to completely remove lipids and proteins from the bone powder.
As used herein, the term "bone graft substitute" refers to a material for filling spaces in bone tissues. For use, the bone graft substitute can be shaped in the form of, for example, putties, pastes, strips, blocks or chips, using a method such as pressing, compression, contact under pressure, packing, solidification or hardening. Alternatively, it can be formulated in the form of, for example, gels, granules, pastes, tablets or pellets, using chemical additives. In addition, it may also be used in the form of powder itself.
When the bone graft substitute is formulated as described above to use, it is preferably used in combination with a biologically active substance. Examples
of the biologically active substance include bone growth-promoting factors, fibrin, bone morphogenetic factors, bone growth-promoting agents, chemotherapeutic agents, antibiotic agents, analgesics, bisphosphonates, strontium salts, fluorine salts, magnesiukm salts, and sodium salts.
In the present invention, the step (b) of soaking the bone powder in the organic solvent is carried out to remove fatty substances remaining in the horse bone powder. The organic solvent is preferably the mixed solvent of chloroform and methanol. The ratio of chloroform: methanol in the mixed solvent may be 2-8: 8-2, and preferably 1 :1.
In the present invention, the step (d) of treating the bone powder with sodium hypochlorite solution is carried out to degrade and remove proteins remaining in the horse bone powder in a water-soluble state and to inactivate denatured prion proteins that cause mad cow disease. In the step (d), sodium hypochlorite may be used in the 2-20% (w/v) solution of sodium hypochlorite, and preferably the 4% (w/v) solution of sodium hypochlorite.
In the present invention, the heat-treatment temperature in the step (g) is preferably 550-650 °C . Also, steps (d) and (e) are carried out to remove proteins and organic substances. In the step (f), the bone powder is hydrothermally treated at 120-125 °C for more than 30 minutes under a pressure, and preferably 3 hours, to degrade and remove proteins from the bone powder.
Furthermore, the preparation method according to the present invention may additionally comprise, after the step (g), the step of sieving the heat-treated bone powder through the sieves having mesh size range of 212-425 μm, 425-1000 μm, 1000-2000 μm and 1000-3000 μm, respectively.
In another aspect, the present invention relates to the bone graft substitute composition containing, as an active ingredient, horse bone powder, which is prepared according to the said method and has no risk of infection with mad cow disease and from which fatty substances, lipids and proteins have been removed so as not to cause a xenogenic immune response.
The bone graft substitute composition according to the present invention preferably additionally contains one or more biologically active substances selected from the group consisting of bone growth-promoting factors, fibrin, bone morphogenetic factors, bone growth agents, chemotherapeutic agents, antibiotic agents, analgesics, bisphosphonates, strontium salts, fluorine salts, magnesiukm salts, and sodium salts. Also, the bone graft substitute composition according to the present invention preferably additionally contains one or more chemical compounds selected from the group consisting of hyaluronic acid, chondroitin sulfate, alginate, chitosan, collagen, hydroxyapatite, calcium carbonate, calcium phosphate, calcium sulfate and ceramics.
Examples of the growth factors include BMP (bone morphogenic protein), PDGF (platelet-derived growth factor), TGF-beta (transgenic growth factor), IGF-I (insulin-like growth factor), IGF-II, FGF (fibroblast growth factor) and BGDF-II (beta-2-microglobulin). Examples of the bone morphogenetic factors include osteocalcin, bonesialoprotein, osteogenin and BMP. As the bone growth- promoting agent, any substance may be used without limitation, as long as it is harmless to the human body and promote bone growth. Examples of the bone growth-promoting agents include peptides or nucleic acids, which promote bone formation, and antagonists against substances which inhibit bone formation.
In the present invention, the chemical additives that are used to formulate the bone graft substitute include hyaluronic acid, collagen, hydroxyapatite, calcium carbonate, calcium phosphate, calcium sulfate and ceramics. Depending on the
kind of chemical additive, the bone graft substitute can be formulated in the form of gels, strips, granules, chips, tablets or pastes.
In the present invention, when the chemical compound is hyaluronic acid, the bone graft substitute can be formulated into a gel-type bone graft substitute composition.
In the present invention, the step of treating the bone powder with sodium hypochlorite is preferably carried out for more than 72 hours in order to remove prion and the remaining proteins.
Examples
Hereinafter, the present invention will be described in further detail with reference to examples. It will be obvious to those skilled in the art that these examples are illustrative purposes only and are not to be construed to limit the scope of the present invention.
Example 1 : Method for preparing bone graft substitute
[Pretreatment and powdering process]
Bone taken from the equine femur was cut with a bone cutter into pieces having a size of about 5 cm3. The bone pieces were soaked in purified water for 24 hours to remove blood components from the bone. The bone pieces, washed with deionized water, were boiled in purified water for 72 hours while replacing purified water at the interval of 12 hours, thus primarily removing fatty substances and proteins from the bone. The bone pieces, from which fat and proteins have been primarily removed, were completely dried in an oven at 60 "C for 24 hours and crushed with a pulverizer to a size of less than 10 mm3.
[Degreasing process]
1 g of the bone powder was added to 20 ml of the mixed solvent of chloroform and methanol (1 :1 v/v), and the solution was shaken at the revolution speed of
120 rpm for 24 hours to degrease the bone powder. To remove the solvent from the degreased bone powder, 1 g of the bone powder was added to 50 g of purified water and shaken at 120 rpm for 12 hours, thus removing the solvent from the powder. Herein, the purified water was replaced with fresh purified water at a 2-hr interval in order to increase water- washing efficiency. The water- washed bone powder was completely dried in the oven at 60 °C .
[Deproteinizing process]
1 g of the degreased dried bone powder was added to 20 ml of the 4% (w/v) solution of sodium hypochlorite and shaken at a revolution speed of 120 rpm for 72 hours to remove proteins from the bone powder and to inactivate a prion protein that causes mad cow disease. To remove the solvent from the deproteinized bone powder, 1 g of the bone powder was added to 50 g of purified water and shaken at 120 rpm for 72 hours, thus removing the remaining sodium hypochlorite. Herein, the purified water was replaced with fresh purified water at a 2-hr interval for 12 hours after the start of shaking, and then replaced with fresh purified water at a 12-hr interval. 1 g of the water- washed bone powder was added to 50 g of purified water and hydrothermally treated at 121 °C for 3 hours under a pressure. Finally, the bone powder was completely dried in an oven at 60 °C .
[Thermal treatment process]
The degreased, deproteinized, dried bone powder was heat-treated at high temperature to remove the remaining lipids and proteins. An electric furnace used in the heat-treatment was heated at a rate of 2 °C/min, and the bone powder was thermally treated at 600 °C for 3 hours, and then cooled in the furnace.
[Sieving process]
The thermally treated bone powder was sieved through sieves having mesh sizes of 212-425 μm, 425-1000 μm, 1000-2000 μm and 1000-3000 μm, respectively, and the sieved bone powder was washed several times with purified water to remove fine dust remaining on the surface thereof. The water-washed powder was dried in an oven at 60 °C for 24 hours and then collected for use as a bone graft substitute.
The prepared bone graft substitute was analyzed by XRD and, as a result, it could be seen that the bone graft substitute consisted of pure apatite crystals (see FIG.
1).
Example 2: Method for preparing bone graft substitute composition
20 g of hyaluronic acid was added to 100 g of demineralized water to prepare a viscous hyaluronic acid solution. To this solution, 10 g of the bone powder prepared in Example 1 was added, thus preparing an injectable paste.
INDUSTRIAL APPLICABILITY
As described above, the present invention provides a method for preparing a bone graft substitute, which comprises treating horse bone with a sodium hypochlorite solution, followed by hydrothermal treatment and high-temperature treatment. Also, the present invention provides the bone graft substitute composition
containing the bone graft substitute prepared according to said method. According to the present invention, a bone graft substitute, which, when transplanted into the human body, does not cause immune responses and has no risk of infection with organic pathogenic substances such as a denatured prion protein that causes mad cow disease, can be prepared in a simple manner by effectively removing fatty substances and organic substances from horse bone having a structure highly similar to that of human bone.
While the present invention has been described in detail with reference to specific features, it will be apparent to those skilled in the art that this description is only for a preferred embodiment and does not limit the scope of the present invention. Thus, the substantial scope of the present invention will be defined by the appended claims and equivalents thereof.
Claims
THE CLAIMS
What is Claimed is:
L A method for preparing a bone graft substitute using horse bone, the method comprising the steps of:
(a) boiling horse bone, from which blood components have been removed, in purified water, to remove fatty substances and proteins from the bone, and drying the boiled bone; (b) crushing the dried bone, and soaking and shaking the bone powder in an organic solvent;
(c) removing the organic solvent and drying the remaining bone powder;
(d) treating the dried bone powder with a 2-20% (w/v) solution of sodium hypochlorite; (e) removing the sodium hypochlorite solution and impurities from the bone powder, and drying the remaining bone powder;
(f) adding purified water to the bone powder, treating hydrothermally the bone powder solution at 120-125 °C for 30 minutes to 5 hours under a pressure, and drying the hydrothermally treated powder; and (g) heat-treating the dried bone powder at 500-1000 °C for 1-24 hours to completely remove lipids and proteins from the bone powder.
2. The method for preparing a bone graft substitute using horse bone according to claim 1, wherein the organic solvent is a mixed solvent of chloroform and methanol.
3. The method for preparing a bone graft substitute using horse bone according to claim 1, wherein the concentration of sodium hypochlorite solution is 4% (w/v).
4. The method for preparing a bone graft substitute using horse bone according to claim 1, wherein the thermal treatment temperature in the step (g) is 550-650 °C .
5. The method for preparing a bone graft substitute using horse bone according to claim 1 , which additionally comprises a step of sieving the thermally treated bone powder through sieves having mesh sizes of 212-425 μm, 425-1000 μm, 1000- 2000 μm or 1000-3000 μm, after the step (g).
6. A bone graft substitute composition containing, as an active ingredient, horse bone powder, which is prepared by the method of any one claim among claims 1-
5, and has no risk of infection with mad cow disease and from which fatty substances, lipids and proteins have been removed so as not to cause a xenogenic immune response.
7. The bone graft substitute composition according to claim 6, which additionally contains one or more biologically active substances selected from the group consisting of bone growth-promoting factors, fibrin, bone morphogenetic factors, bone growth agents, chemotherapeutic agents, antibiotic agents, analgesics, bisphosphonates, strontium salts, fluorine salts, magnesiukm salts, and sodium salts.
8. The bone graft substitute composition according to claim 6, which additionally contains one or more chemical compounds selected from the group consisting of hyaluronic acid, chondroitin sulfate, alginate, chitosan, collagen, hydroxyapatite, calcium carbonate, calcium phosphate, calcium sulfate and ceramics.
9. The bone graft substitute composition according to claim 8, wherein the chemical compound is hyaluronic acid.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060088257A KR100842012B1 (en) | 2006-09-12 | 2006-09-12 | Metohd for Preparing Bone Grafting Substitute from Horse Bone |
KR10-2006-0088257 | 2006-09-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008032928A1 true WO2008032928A1 (en) | 2008-03-20 |
Family
ID=39183953
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2007/003686 WO2008032928A1 (en) | 2006-09-12 | 2007-07-31 | Method for preparing bone grafting substitute from horse bone |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR100842012B1 (en) |
WO (1) | WO2008032928A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2478394C1 (en) * | 2011-11-23 | 2013-04-10 | Федеральное государственное бюджетное учреждение "Российский научный центр "Восстановительная травматология и ортопедия" имени академика Г.А. Илизарова" Министерства здравоохранения и социального развития Российской Федерации | Biomaterial for compensation of bone defects and method of its obtaining |
EP2760490A4 (en) * | 2011-09-29 | 2015-05-27 | Collagen Matrix Inc | Method of preparing porous carbonate apatite from natural bone |
US9238090B1 (en) | 2014-12-24 | 2016-01-19 | Fettech, Llc | Tissue-based compositions |
RU2574935C2 (en) * | 2014-04-09 | 2016-02-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Омский государственный университет им. Ф.М. Достоевского" | Method for separating organic and mineral components of bone tissue |
WO2017139250A1 (en) | 2016-02-09 | 2017-08-17 | CreOsso LLC | Antimicrobial composition for inhibiting microbial organisms in allograft and the method thereof |
US9855365B2 (en) | 2011-11-23 | 2018-01-02 | Chungbuk National University Industry-Academic Cooperation Foundation | Production method for biomedical and industrial material using ceramic derived from birds' beaks |
US10286104B2 (en) | 2011-09-29 | 2019-05-14 | Collagen Matrix, Inc. | Method of preparing porous carbonate apatite from natural bone |
WO2023027663A1 (en) * | 2021-08-27 | 2023-03-02 | Erciyes Universitesi | A graft for maxillary sinus lifting treatment and production thereof |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101139337B1 (en) * | 2010-02-09 | 2012-05-03 | 조선대학교기술지주 주식회사 | Grafting material for teeth bone and method of it |
KR101381108B1 (en) * | 2011-01-24 | 2014-04-11 | 서울대학교산학협력단 | Nano ceramic bone cement using animal bone and method for preparing the same |
KR101348335B1 (en) * | 2011-07-08 | 2014-01-03 | 주식회사 나이벡 | Osteoconductive Bone graft and use thereof |
KR101379894B1 (en) | 2011-11-04 | 2014-04-04 | 전남대학교산학협력단 | Bone graft materials using transgenic pig bone, method of preparing the same, and ceramic materials for biomedical application comprising the same, and |
KR20140045272A (en) * | 2012-10-08 | 2014-04-16 | 전남대학교산학협력단 | Method for preparing low crystalline ceramics derived from animal bone |
KR101348336B1 (en) * | 2012-12-12 | 2014-01-06 | 서울대학교산학협력단 | Osteoconductive Bone graft and use thereof |
KR101473447B1 (en) * | 2014-03-14 | 2014-12-24 | 서울대학교산학협력단 | Nano ceramic bone cement using animal bone and method for preparing the same |
KR101848289B1 (en) * | 2016-05-20 | 2018-04-12 | 디엠씨휴먼사이언스 주식회사 | Animal-derived tissue manufacturing method using the natural hydroxy apatite |
KR102316879B1 (en) * | 2018-07-27 | 2021-10-26 | 서울대학교 산학협력단 | Scaffold for regenerating periodontal tissue containing horse bone-derived nanoceramics and PCL and its manufacturing method |
KR102209893B1 (en) * | 2018-08-20 | 2021-02-01 | 김범수 | Bone grafting material from harts horn and antler, and method for preparing thw same |
KR20230092515A (en) | 2021-12-17 | 2023-06-26 | 농업회사법인 주식회사 천마 | Method for preparing xenograft bone graft material using cancellous bone derived from femur of horse |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4678470A (en) * | 1985-05-29 | 1987-07-07 | American Hospital Supply Corporation | Bone-grafting material |
US5356629A (en) * | 1991-07-12 | 1994-10-18 | United States Surgical Corporation | Composition for effecting bone repair |
US5417975A (en) * | 1988-06-02 | 1995-05-23 | Osteomedical Limited | Chemical Compound |
US6214049B1 (en) * | 1999-01-14 | 2001-04-10 | Comfort Biomedical, Inc. | Method and apparatus for augmentating osteointegration of prosthetic implant devices |
US20040091459A1 (en) * | 2001-09-10 | 2004-05-13 | Nimni Marcel E. | Bone graft material incorporating demineralized bone matrix and lipids |
US20060014283A1 (en) * | 1999-11-25 | 2006-01-19 | Oscotec, Inc. | Inorganic bone graft materials using animal bone and method for preparing thereof |
US20060149362A1 (en) * | 2004-12-30 | 2006-07-06 | Pedrozo Hugo A | Orthopaedic implant for vascularization of the femoral head |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0818829B2 (en) * | 1989-02-20 | 1996-02-28 | 久直 禅野 | Method for producing calcium material mainly composed of natural calcium compound |
DE19681246B4 (en) * | 1995-12-25 | 2004-04-29 | Matsushita Electric Works Ltd., Kadoma-Shi | Device for effecting relaxation |
KR100393469B1 (en) * | 1999-01-02 | 2003-08-06 | 정필훈 | Bone Substitutes using animal bones and their reinforcement technique |
-
2006
- 2006-09-12 KR KR1020060088257A patent/KR100842012B1/en active IP Right Grant
-
2007
- 2007-07-31 WO PCT/KR2007/003686 patent/WO2008032928A1/en active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4678470A (en) * | 1985-05-29 | 1987-07-07 | American Hospital Supply Corporation | Bone-grafting material |
US5417975A (en) * | 1988-06-02 | 1995-05-23 | Osteomedical Limited | Chemical Compound |
US5356629A (en) * | 1991-07-12 | 1994-10-18 | United States Surgical Corporation | Composition for effecting bone repair |
US6214049B1 (en) * | 1999-01-14 | 2001-04-10 | Comfort Biomedical, Inc. | Method and apparatus for augmentating osteointegration of prosthetic implant devices |
US20060014283A1 (en) * | 1999-11-25 | 2006-01-19 | Oscotec, Inc. | Inorganic bone graft materials using animal bone and method for preparing thereof |
US20040091459A1 (en) * | 2001-09-10 | 2004-05-13 | Nimni Marcel E. | Bone graft material incorporating demineralized bone matrix and lipids |
US20060149362A1 (en) * | 2004-12-30 | 2006-07-06 | Pedrozo Hugo A | Orthopaedic implant for vascularization of the femoral head |
Non-Patent Citations (4)
Title |
---|
"Office of Health and Safety (OHS), USA", BMBL SECTION VII - AGENT SUMMARY, 17 June 1999 (1999-06-17), Retrieved from the Internet <URL:http://www.cdc.gov/od/ohs/biosfty/bmbl4/bmbl4s7d.htm> * |
"WHO infection control guidelines for transmissible spongiform encephalopathies", REPORT OF A WHO CONSULTATION, GENEVA, SWITZERLAND, 23 March 1999 (1999-03-23) - 26 March 1999 (1999-03-26), Retrieved from the Internet <URL:http://www.whqlibdoc.who.int/hq/2000/WHO_CDS_CSR_APH_2002.3.pdf> * |
ASLAN M. ET AL.: "The Effect of Hyaluronic Acid-supplement Bone Graft in Bone Healing: Experimental Study in Rabbits", JOURNAL OF BIOMATERIALS APPLICATIONS, vol. 20, January 2006 (2006-01-01), pages 209 - 220 * |
CARDONE F. ET AL.: "Inactivation of transmissible spongiform encephalopathy agents in food products by ultra high pressure-temperature treatment", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1764, 24 February 2006 (2006-02-24), pages 558 - 562, Retrieved from the Internet <URL:http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B73DJ-4JBGGFR-1&_user=981501&_coverDate=03%F31%2F2006&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C000048939&_version=1&_urlVersion=0&_userid=981501&md5-4557cdd707385010570db5a-4ac253eee> * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2760490A4 (en) * | 2011-09-29 | 2015-05-27 | Collagen Matrix Inc | Method of preparing porous carbonate apatite from natural bone |
US10286104B2 (en) | 2011-09-29 | 2019-05-14 | Collagen Matrix, Inc. | Method of preparing porous carbonate apatite from natural bone |
RU2478394C1 (en) * | 2011-11-23 | 2013-04-10 | Федеральное государственное бюджетное учреждение "Российский научный центр "Восстановительная травматология и ортопедия" имени академика Г.А. Илизарова" Министерства здравоохранения и социального развития Российской Федерации | Biomaterial for compensation of bone defects and method of its obtaining |
US9855365B2 (en) | 2011-11-23 | 2018-01-02 | Chungbuk National University Industry-Academic Cooperation Foundation | Production method for biomedical and industrial material using ceramic derived from birds' beaks |
RU2574935C2 (en) * | 2014-04-09 | 2016-02-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Омский государственный университет им. Ф.М. Достоевского" | Method for separating organic and mineral components of bone tissue |
US9238090B1 (en) | 2014-12-24 | 2016-01-19 | Fettech, Llc | Tissue-based compositions |
US11938246B2 (en) | 2014-12-24 | 2024-03-26 | Fettech, Llc | Tissue-based compositions and methods of use thereof |
WO2017139250A1 (en) | 2016-02-09 | 2017-08-17 | CreOsso LLC | Antimicrobial composition for inhibiting microbial organisms in allograft and the method thereof |
EP3413844A4 (en) * | 2016-02-09 | 2019-10-02 | Creosso LLC | Antimicrobial composition for inhibiting microbial organisms in allograft and the method thereof |
AU2017218424B2 (en) * | 2016-02-09 | 2022-01-06 | Rutgers, The State University Of New Jersey | Antimicrobial composition for inhibiting microbial organisms in allograft and the method thereof |
US11224678B2 (en) | 2016-02-09 | 2022-01-18 | Rutgers, The State University Of New Jersey | Antimicrobial composition for inhibiting microbial organisms in allograft and the method thereof |
WO2023027663A1 (en) * | 2021-08-27 | 2023-03-02 | Erciyes Universitesi | A graft for maxillary sinus lifting treatment and production thereof |
Also Published As
Publication number | Publication date |
---|---|
KR100842012B1 (en) | 2008-06-27 |
KR20080024006A (en) | 2008-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008032928A1 (en) | Method for preparing bone grafting substitute from horse bone | |
EP1453434B1 (en) | Tissue repair compositions and methods for their manufacture and use | |
CA2353240C (en) | Bone material and collagen combination for repair of injured joints | |
US4882149A (en) | Pharmaceutical depot preparation | |
JP3471359B2 (en) | Molding material derived from elongated bone particles and method for producing the same | |
US20060216321A1 (en) | Solvent based processing technologies for making tissue/polymer composites | |
Mucalo | Animal-bone derived hydroxyapatite in biomedical applications | |
WO2008102985A1 (en) | Bioactive apatite having dual structure and method for preparing the same | |
CN112569406B (en) | Bone repair material and preparation method thereof | |
KR101348335B1 (en) | Osteoconductive Bone graft and use thereof | |
Luna-Domínguez et al. | Development and in vivo response of hydroxyapatite/whitlockite from chicken bones as bone substitute using a chitosan membrane for guided bone regeneration | |
AU2020202702A1 (en) | Semi-synthetic powder material, obtained by modifying the composition of a natural marine biomaterial, method for producing same, and applications thereof | |
US8586099B2 (en) | Method for preparing a prion-free bond grafting substitute | |
KR101348336B1 (en) | Osteoconductive Bone graft and use thereof | |
PINHOLT et al. | Alveolar ridge augmentation in rats by combined hydroxylapatite and osteoinductive material | |
Karalashvili et al. | Decellularized bovine bone graft for zygomatic bone reconstruction | |
KR20130115781A (en) | Natural bone regeneration material containing minerals derived from human bone | |
WO2015009256A1 (en) | Bone graft from ostrich eggshell powder and its preparation method | |
KR100635385B1 (en) | Method for Preparing a Prion-free Bone Grafting Substitute | |
KR101139660B1 (en) | A method for making bone filling material containing dbm | |
RU2393819C1 (en) | Method of preparing prion-free bone graft substitute | |
PL232501B1 (en) | Method for obtaining a transplant for regeneration of bone tissue, preferably human and the transplant for regeneration of bone tissue, preferably human | |
Aval et al. | Histological Assessment of Bone Regeneration by Octacalcium Phosphate and Bone Matrix Gelatin Composites in a Rat Mandibular Defect Model | |
PL232494B1 (en) | Method for obtaining a transplant of cortical spongy bone debris for regeneration of bone tissue, and the transplant for this regeneration | |
Katthagen et al. | Bone-Replacement Materials |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07793341 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07793341 Country of ref document: EP Kind code of ref document: A1 |